CA3109623C - Composes de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington - Google Patents

Composes de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington Download PDF

Info

Publication number
CA3109623C
CA3109623C CA3109623A CA3109623A CA3109623C CA 3109623 C CA3109623 C CA 3109623C CA 3109623 A CA3109623 A CA 3109623A CA 3109623 A CA3109623 A CA 3109623A CA 3109623 C CA3109623 C CA 3109623C
Authority
CA
Canada
Prior art keywords
compound
benzimidazol
yield
product
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3109623A
Other languages
English (en)
Other versions
CA3109623A1 (fr
Inventor
Chuan Shih
Chih-Hao Chen
Chiung-Tong Chen
Hwei-Jiung WANG
Kai-Fa Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
National Health Research Institutes
Original Assignee
Academia Sinica
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica, National Health Research Institutes filed Critical Academia Sinica
Publication of CA3109623A1 publication Critical patent/CA3109623A1/fr
Application granted granted Critical
Publication of CA3109623C publication Critical patent/CA3109623C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La présente invention concerne des composés de benzimidazole de formule (I), décrite ci-dessous. Les composés sont des inhibiteurs puissants de la glutaminyl-cyclase humaine. L'invention concerne en outre une composition pharmaceutique contenant l'un de ces composés et un véhicule pharmaceutiquement acceptable, ainsi qu'un procédé de traitement de la maladie d'Alzheimer ou de la maladie de Huntington par administration à un sujet en ayant besoin d'une quantité efficace d'un tel composé.
CA3109623A 2018-08-31 2019-08-30 Composes de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington Active CA3109623C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201861725421P 2018-08-31 2018-08-31
US61/725,421 2018-08-31
PCT/US2019/048971 WO2020047360A1 (fr) 2018-08-31 2019-08-30 Composés de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington

Publications (2)

Publication Number Publication Date
CA3109623A1 CA3109623A1 (fr) 2020-03-05
CA3109623C true CA3109623C (fr) 2023-01-24

Family

ID=69643780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109623A Active CA3109623C (fr) 2018-08-31 2019-08-30 Composes de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington

Country Status (5)

Country Link
KR (1) KR102405760B1 (fr)
AU (1) AU2019333295B2 (fr)
CA (1) CA3109623C (fr)
SG (1) SG11202101274XA (fr)
WO (1) WO2020047360A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022203580A1 (en) * 2021-09-17 2023-04-06 Academia Sinica Methods of Increasing Cell Phagocytosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420684B2 (en) * 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5667440B2 (ja) * 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) * 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2481823T3 (es) * 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)

Also Published As

Publication number Publication date
AU2019333295B2 (en) 2021-07-29
WO2020047360A1 (fr) 2020-03-05
AU2019333295A1 (en) 2021-03-04
KR20210089129A (ko) 2021-07-15
KR102405760B1 (ko) 2022-06-07
SG11202101274XA (en) 2021-03-30
WO2020047360A8 (fr) 2021-09-10
CA3109623A1 (fr) 2020-03-05

Similar Documents

Publication Publication Date Title
KR101214665B1 (ko) 트리아졸 유도체 또는 그의 염
US6620831B2 (en) Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
RU2733750C2 (ru) Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
WO1999019303A1 (fr) Derives de pyrazole
CA2978823A1 (fr) Inhibiteurs a petite molecule de lactate deshydrogenase et procedes pour les utiliser
HRP20041008A2 (en) Triazole derivatives as tachykinin receptor antagonists
WO2002062792A9 (fr) Inhibiteur de jnk
JP2010500999A (ja) ベータ−セクレターゼの阻害剤としてのイミダゾールアミン
US10556898B2 (en) Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
KR102519948B1 (ko) 암 치료용 화합물 및 조성물
CA2897469A1 (fr) Derives de pyridine comme modulateurs allosteriques positifs de recepteur muscarinique m1
WO2012036278A1 (fr) Inhibiteur de transporteur de glycine
RU2605600C2 (ru) Амино-замещенные производные 3-гетероароиламинопропионовой кислоты и их применение в качестве фармацевтических средств
JP2013177318A (ja) ジヒドロピリミジノン誘導体およびその医薬用途
JP5269795B2 (ja) カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体
JP2023540661A (ja) ＣＣＲ８阻害剤を使用してＴｒｅｇｓを標的とする方法および組成物
CA2946754A1 (fr) Inhibiteur de pde10 optiquement actif
JP2007223901A (ja) 複素環化合物およびその用途
MX2007003381A (es) Derivados de 2-acilaminotiazol.
EP2914589B1 (fr) Composés destinés à être utilisés dans le traitement de maladies parasitaires
CA3109623C (fr) Composes de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington
JP2019523237A (ja) 乳酸脱水素酵素の阻害剤としての１ｈ−ピラゾール−１−イル−チアゾールおよびそれらの使用方法
JPH11240832A (ja) アミド若しくはアミン誘導体
US10584120B1 (en) Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease
JP2010504326A (ja) β−セクレターゼを阻害するためのインドリルアルキルピリジン−２−アミン

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220401

EEER Examination request

Effective date: 20220401

EEER Examination request

Effective date: 20220401

EEER Examination request

Effective date: 20220401

EEER Examination request

Effective date: 20220401